NASDAQ:TMCI - Treace Medical Concepts Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.50
  • Forecasted Upside: 98.74 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.34
▼ -0.08 (-0.55%)

This chart shows the closing price for TMCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Treace Medical Concepts Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMCI

Analyst Price Target is $28.50
▲ +98.74% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Treace Medical Concepts in the last 3 months. The average price target is $28.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 98.74% upside from the last price of $14.34.

This chart shows the closing price for TMCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Treace Medical Concepts.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2022BTIG ResearchInitiated CoverageBuy$22.00Medium
3/4/2022Morgan StanleyLower Price TargetOverweight$30.00 ➝ $28.00Low
3/4/2022Stifel NicolausLower Price TargetBuy$37.00 ➝ $32.00Low
1/7/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$30.00Medium
11/5/2021SVB LeerinkLower Price TargetOutperform$38.00 ➝ $32.00High
10/22/2021SVB LeerinkReiterated RatingOutperformLow
5/26/2021Morgan StanleyBoost Price TargetEqual Weight$30.00 ➝ $32.00High
5/18/2021SVB LeerinkInitiated CoverageOutperform$38.00High
5/18/2021JPMorgan Chase & Co.Initiated CoverageOverweight$37.00High
5/18/2021Morgan StanleyInitiated CoverageEqual Weight$30.00High
5/18/2021Stifel NicolausInitiated CoverageBuy$35.00High
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Treace Medical Concepts logo
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Read More

Today's Range

Now: $14.34
Low: $14.06
High: $14.98

50 Day Range

MA: $16.04
Low: $12.93
High: $19.87

52 Week Range

Now: $14.34
Low: $12.48
High: $32.30

Volume

105,886 shs

Average Volume

223,361 shs

Market Capitalization

$792.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Treace Medical Concepts?

The following Wall Street research analysts have issued research reports on Treace Medical Concepts in the last twelve months: BTIG Research, Morgan Stanley, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for TMCI.

What is the current price target for Treace Medical Concepts?

0 Wall Street analysts have set twelve-month price targets for Treace Medical Concepts in the last year. Their average twelve-month price target is $28.50, suggesting a possible upside of 97.6%.
View the latest price targets for TMCI.

What is the current consensus analyst rating for Treace Medical Concepts?

Treace Medical Concepts currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TMCI will outperform the market and that investors should add to their positions of Treace Medical Concepts.
View the latest ratings for TMCI.

What other companies compete with Treace Medical Concepts?

How do I contact Treace Medical Concepts' investor relations team?

Treace Medical Concepts' physical mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The company's listed phone number is 904-373-5940 and its investor relations email address is [email protected] The official website for Treace Medical Concepts is www.treace.com. Learn More about contacing Treace Medical Concepts investor relations.